Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

Sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Study ID
NCT05782972
Phase
PHASE4
Status
Active Not Recruiting

Conditions

  • Metabolic Associated Fatty Liver Disease

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients. The primary outcomes are the improvement of liver inflammation or fibrosis parameters after 24 weeks treatment. The adverse events were also recorded.

Key Dates

Start date
Mar 11, 2023
Status verified
Feb 2025
Primary completion
Nov 30, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: dapagliflozin (Forxiga) treatment
    The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks

Primary Outcome Measure

Change of liver inflammatory marker [ Time Frame: 24 weeks ]

Related Studies